SEI Investments’s Aclaris Therapeutics ACRS Stock Holding History

SEI Investments’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$974K	Buy	185,258 +46,480	+33%	+$265K	﹤0.01%	2319
2026 Q2	$734K	Sell	138,778 -78,376	-36%	-$350K	﹤0.01%	2468
2026 Q1	$814K	Buy	+217,154	New	+$733K	﹤0.01%	2452
2025 Q2	–	Sell	-25,189	Closed	-$38.5K	–	2785
2025 Q1	$38.5K	Buy	+25,189	New	+$53.7K	﹤0.01%	2696
2019 Q2	–	Sell	-3,277	Closed	-$18K	–	2378
2019 Q1	$18K	Sell	3,277 -10,710	-77%	-$71K	﹤0.01%	2752
2018 Q4	$103K	Buy	13,987 +13,951	+38,753%	+$144K	﹤0.01%	2193
2018 Q3	$0	Buy	36 +35	+3,500%	+$600	﹤0.01%	2507
2018 Q2	$0	Sell	1 -1,048	-100%	-$19.4K	﹤0.01%	3599
2018 Q1	$18K	Buy	1,049 +169	+19%	+$3.58K	﹤0.01%	2676
2017 Q4	$22K	Sell	880 -7,391	-89%	-$180K	﹤0.01%	2573
2017 Q3	$214K	Sell	8,271 -2,769	-25%	-$74.2K	﹤0.01%	1853
2017 Q2	$300K	Buy	11,040 +10,663	+2,828%	+$290K	﹤0.01%	1771
2017 Q1	$11K	Sell	377 -2,223	-86%	-$64.1K	﹤0.01%	2441
2016 Q4	$71K	Buy	+2,600	New	+$66.3K	﹤0.01%	2043

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Three Bridge Wealth Advisors Los Altos, California $469M AUM 10.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

SEI Investments's ACRS Position: Q3 2026 in Review

SEI Investments increased its Aclaris Therapeutics (ACRS) stake by 33% in Q3 2026, buying an estimated $265K and bringing the position to 185,258 shares worth $974K. The position accounts for ﹤0.01% of the portfolio, ranked #2319.

SEI Investments first reported a position in ACRS in Q4 2016 and has held it in 14 quarters since. 62 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

SEI Investments held 185,258 shares of Aclaris Therapeutics worth $974K as of Q3 2026.
SEI Investments bought 46,480 Aclaris Therapeutics shares in Q3 2026, an estimated $265K.
Aclaris Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q3 2026, its #2319 holding.
SEI Investments first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 14 quarters since.
62 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on SEI Investments's 13F filing for Q3 2026, filed 10 Nov 2026.